$0.01
+0.00 (+0.00%)
Open$0.01
Previous Close$0.01
Day High$0.01
Day Low$0.00
52W High$3,132.00
52W Low—
Volume—
Avg Volume3.78M
Market Cap399.2K
P/E Ratio—
EPS$-205,055.95
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+134,900.0% upside
Current
$0.01
$0.01
Target
$13.50
$13.50
$9.80
$13.50 avg
$19.20
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 11.18B | 10.47B | 180.5K |
| Net Income | -2,873,510,358,333 | -2,421,497,492,977 | -19,611 |
| Profit Margin | -25,708.3% | -24,422.8% | -10.9% |
| EBITDA | -2,290,571,274,425 | -2,037,493,174,816 | -25,362 |
| Free Cash Flow | — | — | -13,693 |
| Rev Growth | +6.8% | +6.8% | +10.1% |
| Debt/Equity | 0.65 | 0.65 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $288.24 | -2.24% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $460.28 | -3.80% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $167.57 | -3.96% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $542.50 | -1.19% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $902.90 | -2.98% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.66 | -2.74% | 28.8 | 23.28B |